Figure 2.
Distribution of time since last intake of rivaroxaban and measured rivaroxaban plasma levels in patients treated with intravenous thrombolysis (IVT) (●) and those not treated with IVT (○). The rivaroxaban plasma level thresholds for IVT recommended (brocken line) and IVT to-beconsedered (continuous line) are indicated.